Conditions: Non-Small Cell Lung Cancer
Keywords: second line non small cell lung cancer NSCLC phase 3 ramucirumab lung cancer docetaxel taxotere
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1253
Healthy volunteers: no

Brief summary:
The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Ramucirumab intervention 2: Placebo (for Ramucirumab) intervention 3: Docetaxel
Intervention descriptions: intervention 1: 10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met intervention 2: Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met intervention 3: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met

Protocol document: